Costs and cost-effectiveness of a large-scale mass testing and treatment intervention for malaria in Southern Province, Zambia

Malaria Journal

Volumn 14, Issue 1, 2015, Pages

  Silumbe, Kafula ^a   Yukich, Joshua O ^b   Hamainza, Busiku ^c   Bennett, Adam ^d   Earle, Duncan ^a   Kamuliwo, Mulakwa ^c   Steketee, Richard W ^a   Eisele, Thomas P ^b   Miller, John M ^a  

^a PATH Malaria Control and Evaluation Partnership in Africa (MACEPA)   (Zambia)

^b TULANE UNIVERSITY   (United States)

^c National Malaria Control Centre   (Zambia)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cost effectiveness; Malaria; Mass testing and treatment

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DRUG COMBINATION; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE;

ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST PER DISABILITY ADJUSTED LIFE YEAR; DISEASE TRANSMISSION; ECONOMIC EVALUATION; HEALTH CARE COST; HUMAN; MALARIA; MASS SCREENING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; WORLD HEALTH ORGANIZATION; ZAMBIA; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIAGNOSTIC TEST; DRUG COMBINATION; ECONOMICS; RANDOMIZED CONTROLLED TRIAL;

ANTIMALARIALS; ARTEMISININS; COST-BENEFIT ANALYSIS; DIAGNOSTIC TESTS, ROUTINE; DRUG COMBINATIONS; ETHANOLAMINES; FLUORENES; MALARIA; MASS SCREENING; ZAMBIA;

EID: 84929627479     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-015-0722-3     Document Type: Article

References (45)

1. WHO. World Malaria Report 2013. Geneva: World Health Organization; 2013.
2. Das P, Horton R. Malaria elimination: worthy, challenging, and just possible. Lancet. 2010;376:1515-7.
3. Moonen B, Cohen JM, Snow RW, Slutsker L, Drakeley C, Smith DL, et al. Operational strategies to achieve and maintain malaria elimination. Lancet. 2010;376:1592-603.
4. Ministry of Health Zambia. National malaria control programme strategic plan for 2011-2015: "Consolidating malaria gains for impact". Lusaka, Zambia: National Malaria Control Programme; 2011.
5. Ministry of Health Zambia. National Malaria Indicator Survey. 2010.
6. Chanda E, Coleman M, Kleinschmidt I, Hemingway J, Hamainza B, Masaninga F, et al. Impact assessment of malaria vector control using routine surveillance data in Zambia: implications for monitoring and evaluation. Malar J. 2012;11:437.
7. WHO. Focus on Zambia. Geneva: World Health Organization; 2011.
8. Barat L, Chipipa J, Kolczak M, Sukwa T. Does the availability of blood slide microscopy for malaria at health centers improve the management of persons with fever in Zambia? Am J Trop Med Hyg. 1999;60:1024-30.
9. Ministry of Health Zambia. Malaria Indicator Survey. 2006.
10. Ministry of Health Zambia. Malaria Indicator Survey. 2008.
11. Bennett A, Yukich J, Miller JM, Vounatsou P, Hamainza B, Ingwe MM, et al. A methodological framework for the improved use of routine health system data to evaluate national malaria control programs: evidence from Zambia. Population Health Metrics. 2014;12:30.
12. Larsen DA, Bennett A, Silumbe K, Hamainza B, Yukich JO, Keating J et al. Population-wide malaria testing and treatment with rapid diagnostic tests and artemetherlumefantrine in southern Zambia: a community randomized step-wedge control trial design. Am J Trop Med Hyg. 2015, [Epub ahead of print]
13. von Seidlein L, Greenwood BM. Mass administrations of antimalarial drugs. Trends Parasitol. 2003;19:452-60.
14. Okell LC, Griffin JT, Kleinschmidt I, Hollingsworth TD, Churcher TS, White MJ, et al. The potential contribution of mass treatment to the control of Plasmodium falciparum malaria. PLoS One. 2011;6:e20179.
15. Crowell V, Briet OJ, Hardy D, Chitnis N, Maire N, Di Pasquale A, et al. Modelling the cost-effectiveness of mass screening and treatment for reducing Plasmodium falciparum malaria burden. Malar J. 2013;12:4.
16. Cost effectiveness and strategic planning (WHO-CHOICE) [ http://www.who.int/choice/en/ ]
17. Drummond MS MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care PRogrammes. Thirdth ed. Oxford: Oxford University Press; 2005.
18. Hutton G, Baltussen R. Cost valuation in resource-poor settings. Health Policy Plan. 2005;20:252-9.
19. OANDA [ http://www.oanda.com/ ]
20. Data: The World Bank [ http://data.worldbank.org ]
21. Chanda P, Hamainza B, Moonga HB, Chalwe V, Banda P, Pagnoni F. Relative costs and effectiveness of treating uncomplicated malaria in two rural districts in Zambia: implications for nationwide scale-up of home-based management. Malar J. 2011;10:159.
22. Global Price Reporting Mechanism for HIV, tuberculosis and malaria [ http://www.who.int/hiv/amds/gprm/en/ ]
23. Lubell Y, Riewpaiboon A, Dondorp AM, von Seidlein L, Mokuolu OA, Nansumba M, et al. Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa. Bull World Health Organ. 2011;89:504-12.
24. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010;376:1647-57.
25. Goodman CA, Coleman PG, Mills AJ. Cost-effectiveness of malaria control in sub-Saharan Africa. Lancet. 1999;354:378-85.
26. Lopez AM CD, Ezzati M, Jamison DT, Murray CJL. Global Burden of Disease and Risk Factors. Washington DC: The International Bank for Reconstruction and Development / The World Bank; 2006.
27. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, et al. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet. 2012;379:413-31.
28. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197-223.
29. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMJ. 2013;346:f1049.
30. Yukich JO, Lengeler C, Tediosi F, Brown N, Mulligan JA, Chavasse D, et al. Costs and consequences of large-scale vector control for malaria. Malar J. 2008;7:258.
31. White MT, Conteh L, Cibulskis R, Ghani AC. Costs and cost-effectiveness of malaria control interventions-a systematic review. Malar J. 2011;10:337.
32. Crowell V, Yukich JO, Briet OJ, Ross A, Smith T. A novel approach for measuring the burden of uncomplicated Plasmodium falciparum malaria. PLoS One. 2013;8:e57297.
33. Talisuna AO, Bloland P, D'Alessandro U. History, dynamics, and public health importance of malaria parasite resistance. Clin Microbiol Rev. 2004;17:235-54.
34. Salman S, Page-Sharp M, Griffin S, Kose K, Siba PM, Ilett KF, et al. Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother. 2011;55:5306-13.
35. Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg. 2007;77:181-92.
36. Shekalaghe SA, Drakeley C, van den Bosch S, ter Braak R, van den Bijllaardt W, Mwanziva C, et al. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malar J. 2011;10:247.
37. von Seidlein L, Walraven G, Milligan PJ, Alexander N, Manneh F, Deen JL, et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Trans R Soc Trop Med Hyg. 2003;97:217-25.
38. De Martin S, von Seidlein L, Deen JL, Pinder M, Walraven G, Greenwood B. Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Trop Med Int Health. 2001;6:442-8.
39. Zulueta J, Kafuko GW, McCrae AW, Cullen JR, Pedersen CK, Wasswa DF. A malaria eradication experiment in the highlands of Kigezi (Uganda). East African Med J. 1964;41:102-20.
40. Garfield RM, Vermund SH. Changes in malaria incidence after mass drug administration in Nicaragua. Lancet. 1983;2:500-3.
41. Molineaux L, GG. The Garki Project. Research on the epidemiology and control of malaria in the Sudan savaanah of west Africa. Geneva, Switzerland: World Health Organization; 1980.
42. Bruxvoort K, Goodman C, Kachur SP, Schellenberg D. How patients take malaria treatment: a systematic review of the literature on adherence to antimalarial drugs. PLoS One. 2014;9:e84555.
43. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Medical Care. 2004;42:200-9.
44. WHO. World Malaria Report. World Health Organization: Geneva; 2011.
45. Zhuang J, Liang Z, Lin T, De Guzman F. Theory and practice in the choice of social discount rate for cost-benefit analysis: a survey. ERD Working Paper n. 94. Manila, Philippines: Asian Development Bank; 2007.